Simple combo could stop hepatitis b passed from mom to baby
NCT ID NCT05705427
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether giving pregnant women with hepatitis B a daily pill (tenofovir) plus giving their newborns a hepatitis B vaccine at birth could safely prevent the virus from passing to the baby. The trial enrolled 317 women in the Democratic Republic of Congo and followed them and their infants for six months after birth. The main goals were to see if the approach was safe, acceptable, and feasible in a real-world setting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tenofovir Disoproxil Fumarate (TDF) and hepatitis B birth-dose vaccine
What this could lead to
If this approach works, it could offer a simple, affordable way to prevent mother-to-child transmission of hepatitis B in low-resource settings.
What could go wrong
This is a feasibility trial, not designed to prove effectiveness. The results may not apply to other regions or populations, and side effects from tenofovir are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Université Protestant au Congo
Kinshasa, Democratic Republic of the Congo